Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | PAK4 | O96013 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46341 | 0.81 | ALDH1A1 (0.35) | HSD17B10HPGDHTTALDH1A1MEN1 | |
| SCHEMBL17418888 | 0.80 | PDE4B (0.43) | HSD17B10PDE4BHPGDHTTALDH1A1 | |
| SCHEMBL17432908 | 0.79 | HSD17B10 (0.34) | HSD17B10HPGDHTTALDH1A1MEN1 | |
| SCHEMBL21377510 | 0.79 | HSD17B10 (0.53) | HSD17B10HPGDHTTALDH1A1MEN1 | |
| SCHEMBL19023154 | 0.79 | HPGD (0.37) | HSD17B10HPGDHTTALDH1A1MEN1 | |
| SCHEMBL8473870 | 0.79 | HSD17B10 (0.34) | HSD17B10PDE4BHPGDHTTALDH1A1 | |
| SCHEMBL8624806 | 0.79 | HSD17B10 (0.35) | HSD17B10HPGDHTTALDH1A1MEN1 | |
| SCHEMBL31682602 | 0.76 | HSD17B10 (0.57) | HSD17B10PDE4BGSK3BHPGDHTT | |
| SCHEMBL16361870 | 0.76 | HSD17B10 (0.57) | HSD17B10PDE4BGSK3BHPGDHTT | |
| SCHEMBL8624679 | 0.76 | HRH3 (0.33) | HSD17B10HPGDHTTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11401272-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| US-20200392143-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | INCYTE CORPORATION | 2020-12-17 | — | — | US | disclosed |
| US-10800779-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800779-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-10-13 | — | — | US | disclosed |
| US-10640503-B2 | Imidazopyridines and imidazopyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-05-05 | — | — | US | disclosed |
| US-10640503-B2 | Imidazopyridines and imidazopyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-05-05 | — | — | US | disclosed |
| EP-3626720-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | Incyte Corporation (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3626720-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | Incyte Corporation (US) | 2020-03-25 | — | — | EP | disclosed |
| US-10556908-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-02-11 | — | — | US | disclosed |
| US-10556908-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-02-11 | — | — | US | disclosed |
| US-5767128-A | ANALGESICS | ADIR ET COMPAGNIE (FR) | 1998-06-16 | — | — | US | disclosed |
| US-5618819-A | ANALGESICS | ADIR ET COMPAGNIE (FR) | 1997-04-08 | — | — | US | disclosed |
| EP-0691339-A1 | Amine derivatives of 1,3-dihydro-2H-pyrrolo(2,3-b)pyridin-2-ones and oxazolo(4,5-b)pyridin-2(3H)-ones, their process of preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1996-01-10 | — | — | EP | disclosed |
| EP-0357675-A4 | PYRIDOOXAZINONE-PYRIDONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES | — | 1992-01-15 | — | — | EP | disclosed |
| WO-1991006300-A1 | NAPHTHERIDINONE- AND PYRIDOOXAZINONE-PYRIDONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING SAME, AND THEIR USES | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-05-16 | — | — | WO | disclosed |
| US-5015638-A | Cardiovascular disorders, cardiotonic agents for congestive he art failure | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-05-14 | — | — | US | disclosed |
| EP-0357675-A1 | PYRIDOOXAZINONE-PYRIDONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1990-03-14 | — | — | EP | disclosed |
| US-4866074-A | Naphtheridinone- and pyridooxazinone-pyridone compounds, cardiotonic compositions including same, and their uses | RORER PHARMACEUTICAL CORPORATION (US) | 1989-09-12 | — | — | US | disclosed |
| US-4822794-A | Pyridooxazinone-pyridone compounds, cardiotonic compositions including the same, and their uses | RORER PHARMACEUTICAL CORPORATION (US) | 1989-04-18 | — | — | US | disclosed |
| WO-1988008705-A1 | PYRIDOOXAZINONE-PYRIDONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1988-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401272-B2 | Heterocyclic compounds as LSD1 inhibitors | KDM1B, KDM1A, DOT1L | HSD17B10 386/4885PDE4B 2827/4885GSK3B 1256/4885 |
| US-20200392143-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, DOT1L | HSD17B10 386/4885PDE4B 2827/4885GSK3B 1256/4885 |
| US-10556908-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | KDM1A, KDM1B, KDM2A | HSD17B10 838/4885PDE4B 2055/4885GSK3B 2601/4885 |
| US-10800779-B2 | Heterocyclic compounds as LSD1 inhibitors | KDM1B, KDM1A, DOT1L | HSD17B10 386/4885PDE4B 2827/4885GSK3B 1256/4885 |
| US-10640503-B2 | Imidazopyridines and imidazopyrazines as LSD1 inhibitors | KDM5A, KDM1A, KDM1B | HSD17B10 1260/4885PDE4B 1180/4885GSK3B 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.